Approval · Notice of Compliance 26193 · 2021
ABRILADA: Notice of Compliance 26193
Issued June 29, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26193
- Date
- June 29, 2021
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
- Canadian reference product
- HUMIRA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABRILADA | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 50 MG per ML